Deutsch English Français

Contact

EP4119571

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP4119571

EP4119571 - NOVEL BISPECIFIC PROTEIN AND USE THEREOF [Right-click to bookmark this link]
Status	Request for examination was made Status updated on 16.12.2022 Database last updated on 28.03.2026
Former	The international publication has been made Status updated on 17.09.2021
Most recent event Tooltip	03.03.2026	New entry: Renewal fee paid
Applicant(s)	For all designated states SL Metagen 2nd FL., Korea Bio Park Bldg. A 700 Daewangpangyo-ro Bundang-gu Seongnam-si, Gyeonggi-do 13488 / KR
	[2023/03]
Inventor(s)	01 / YANG, Sang In 107-603, 80, Songok-ro, Suji-gu Yongin-si Gyeonggi-do 16823 / KR
	02 / AN, In Bok 721ho, 198, Jangmi-ro, Bundang-gu Seongnam-si Gyeonggi-do 13503 / KR
	[2023/03]
Representative(s)	Dehns 10 Old Bailey London EC4M 7NG / GB
	[N/P]
Former [2023/03]	Dehns St. Bride's House 10 Salisbury Square London EC4Y 8JD / GB
Application number, filing date	21767580.0	12.03.2021
	[2023/03]
	WO2021KR03128
Priority number, date	KR20200030727	12.03.2020 Original published format: KR 20200030727
	[2023/03]
Filing language	KO
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2021182928
	Date:	16.09.2021
	Language:	KO
	[2021/37]
	Type:	A1 Application with search report
	No.:	EP4119571
	Date:	18.01.2023
	Language:	EN
	[2023/03]
Search report(s)	International search report - published on:	KR	16.09.2021
	(Supplementary) European search report - dispatched on:	EP	05.03.2024
Classification	IPC:	C07K14/605, C12N15/62, A61K38/26, A61P1/00, A61P3/00	[2023/03]
	CPC:	A61P1/00 (EP,KR,US); C07K14/605 (EP,KR,US); A61K38/26 (KR); A61P3/00 (EP,KR); C12N15/62 (KR); A61K2039/505 (EP); (+) A61K2039/545 (EP); A61K38/00 (EP,US); C07K2317/31 (EP); C07K2317/526 (EP,KR); C07K2317/53 (KR); C07K2319/00 (EP); C07K2319/30 (EP,KR,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/03]
Title	German:	NEUES BISPEZIFISCHES PROTEIN UND VERWENDUNG DAVON	[2023/03]
	English:	NOVEL BISPECIFIC PROTEIN AND USE THEREOF	[2023/03]
	French:	NOUVELLE PROTÉINE BISPÉCIFIQUE ET SON UTILISATION	[2023/03]
Entry into regional phase	11.10.2022	Translation filed
	11.10.2022	National basic fee paid
	11.10.2022	Search fee paid
	11.10.2022	Designation fee(s) paid
	11.10.2022	Examination fee paid
Examination procedure	11.10.2022	Examination requested [2023/03]
	20.09.2024	Date on which the examining division has become responsible
	25.09.2024	Amendment by applicant (claims and/or description)
Fees paid	Renewal fee
	12.01.2023	Renewal fee patent year 03
	15.02.2024	Renewal fee patent year 04
	27.02.2025	Renewal fee patent year 05
	27.02.2026	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XY] WO2006010143 (NEOSE TECHNOLOGIES INC et al.) [X] 1-4,9,10,12-15 * paragraph [0086] - paragraph [0088] * * claims 1-17 *[Y] 5-8,11
		[XY] EP1767545 (BIOCOMPATIBLES UK LTD et al.) [X] 1,9,10,12-15 * paragraph [0017] * * figure 1 *[Y] 5-8,11
		[Y] EP3241850 (GENEXINE INC et al.) [Y] 5-8,11 * figures 1-3 * * paragraph [0017] *
		[Y] WO2018071919 (XENCOR INC et al.) [Y] 5-8,11 * paragraph [0168] - paragraph [0170] * * claims *
		[XP] WO2020231199 (PROGEN CO LTD et al.) [XP] 1-15 * examples 4, 5 * * tables 5, 10 * * paragraph [0009] - paragraph [0017] * * paragraph [0063] *
		[XP] EP3995508 (PROGEN CO LTD et al.)
		[A] K.B. MADSEN ET AL: "Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study", REGULATORY PEPTIDES, vol. 184, 1 June 2013 (2013-06-01), pages 30 - 39, XP055183143, ISSN: 0167-0115, DOI: 10.1016/j.regpep.2013.03.025 [A] 1-15 * abstract * DOI: http://dx.doi.org/10.1016/j.regpep.2013.03.025
		[A] WISMANN PERNILLE ET AL: "Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice", PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 192, 11 March 2018 (2018-03-11), pages 72 - 81, XP085410848, ISSN: 0031-9384, DOI: 10.1016/J.PHYSBEH.2018.03.004 [A] 1-15 * abstract * * page 73, column r, paragraph 2 * * table 1 * * page 77, column l, paragraph 2 * DOI: http://dx.doi.org/10.1016/j.physbeh.2018.03.004
		[A] WILLIAM R. STROHL: "Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters", BIODRUGS, vol. 29, no. 4, 16 July 2015 (2015-07-16), NZ, pages 215 - 239, XP055564076, ISSN: 1173-8804, DOI: 10.1007/s40259-015-0133-6 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1007/s40259-015-0133-6
	International search	[Y] KR101825049 (주식회사 제넥신) [Y] 2-4,18-21 * See abstract; and paragraphs [0017] and [0042]-[0051]. *
		[A] US2014193407 (HERRING CHRISTOPHER et al.) [A] 1-32 * See entire document. *
		[A] KR20190065346 (XENCOR INC et al.) [A] 1-32 * See entire document. *
		[A] WISMANN PERNILLE; PEDERSEN SREN L.; HANSEN GITTE; MANNERSTEDT KARIN; PEDERSEN PHILIP J.; JEPPESEN PALLE B.; VRANG NIELS; FOSGERAU: "Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice", PHYSIOLOGY & BEHAVIOR, vol. 192, 11 March 2018 (2018-03-11), pages 72 - 81, XP085410848, ISSN: 0031-9384, DOI: 10.1016/j.physbeh.2018.03.004 [A] 5,7,26-32 DOI: http://dx.doi.org/10.1016/j.physbeh.2018.03.004
	by applicant	US2010239554
		KR100897938
		EP1442254
		GUTNIAK ET AL., N. ENGL. J. MED., vol. 326, 1992, pages 1316 - 1322
		KUNKEL ET AL., NEUROGASTROENTEROL. MOTIL., vol. 23, 2011, pages 739 - e328
		KOEHLER ET AL., CELL METABOL, vol. 21, no. 3, 2015, pages 379 - 391
		MADSEN ET AL., REGUL. PEPT., vol. 184, 2013, pages 30 - 39
		CAPON ET AL., NATURE, vol. 337, 1989, pages 525 - 531
		CALICETIVERONESE, ADV. DRUG DELIVERY REV., vol. 55, 2003, pages 1261 - 1277
		SCHELLENBERGER ET AL., NAT. BIOTECHNOL., vol. 27, 2009, pages 1186 - 1190
		PRO-ALA-SERSCHLAPSCHY ET AL., PROTEIN ENG. DES. SEL., vol. 26, 2013, pages 489 - 501
		FLOSS ET AL., TRENDS BIOTECHNOL, vol. 28, 2010, pages 37 - 45
		SCHLAPSCHY ET AL., PROTEIN ENG. DES. SEL., vol. 20, 2007, pages 273 - 284
		HUANG ET AL., EUR. J. PHARM. BIOPHARM., vol. 74, no. 3, 2010, pages 435 - 441
		SHEFFIELD ET AL., CELL PHYSIOL. BIOCHEM., vol. 45, no. 2, 2018, pages 772 - 782
		STROHL, W. R., BIODRUGS, vol. 29, no. 4, 2015, pages 215 - 239
		YANG ET AL., J. MED. CHEM., vol. 61, 2018, pages 3218 - 3223
		LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
		DEFRONZO ET AL., DIABETES CARE, vol. 28, 2005, pages 1092 - 1100
		REMINGTON'S PHARMACEUTICAL SCIENCES
		CHARRON, J. BIOL. CHEM., vol. 270, 1995, pages 25739 - 25745
		PAGANO ET AL., SCIENCE, vol. 255, 1992, pages 1144 - 1147
		GYURIS ET AL., CELL, vol. 75, 1995, pages 791 - 803
		WEI ET AL., ONCOTARGET, vol. 8, no. 31, 2017, pages 51037 - 51049
		RIDGWAY ET AL., PROTEIN ENG, vol. 9, no. 7, 1996, pages 617 - 621
		CARTER, P., J. IMMUNOL. METHODS, vol. 48, no. 1-2, 2001, pages 7 - 15
		MERCHANT ET AL., NAT. BIOTECHNOL., vol. 16, no. 7, 1998, pages 677 - 681

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.